NCT00821054 - A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2009

Primary Completion Date

March 22, 2011

Study Completion Date

March 22, 2011

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib

Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.

Trial Locations (5)

14263

GSK Investigational Site, Buffalo

29605

GSK Investigational Site, Greenville

T6G 1Z2

GSK Investigational Site, Edmonton

H2W 1T8

GSK Investigational Site, Montreal

1066 CX

GSK Investigational Site, Amsterdam